Dexamethasone for Reduction of Post Thoracotomy Pain Syndrome
Unknown statusNot applicableNCT02112864
View the official record on ClinicalTrials.gov Recruiting status changes often. Contact the study team listed on ClinicalTrials.gov, and talk to your doctor before joining a study.
Brief summary (from the registry)
Post thoracotomy pain syndrome still affects 50% of patients after a thoracic surgery. Pathogenesis is unclear but there is growing evidence that neuro inflammation may play a significant role. Dexamethasone is a very potent anti-inflammatory drug. The hypothesis of this study is that dexamethasone, given pre operatively, would help reduce the incidence of post thoracotomy pain syndrome 3 months after surgery, by reducing the inflammatory response, in patients undergoing elective thoracic surgery that includes thoracic epidural analgesia.
Study details
- Official title
- Impact of Dexamethasone on the Post Operative Inflammatory Response and on the Occurrence of Post Thoracotomy Pain Syndrome
- Conditions
- Chronic Pain
- Dexamethasone
- Thoracic Surgery
- Cytokines
- Interventions
- Sponsor
- Maisonneuve-Rosemont Hospital
- Start date
- 2014-05
- Primary completion
- 2024-12
- Sex
- All
- Age range
- from 18 Years to 75 Years
- Results posted
- No results posted in this snapshot
- Countries
- Canada
- Total sites listed
- 1
Eligibility criteria
Show eligibility criteria (verbatim from the registry)
Inclusion Criteria: * elective thoracic surgery using a thoracotomy incision and thoracic epidural analgesia * ASA I-III * age 18-75 yo Exclusion Criteria: * contra-indication to thoracic epidural analgesia * patient refusal * patients already taking cortisone or dexamethasone * patients on chronic opioid medication
Canadian sites (1)
Source: ClinicalTrials.gov (US National Library of Medicine), snapshot October 2026. Check the registry for current recruiting status. Record: https://clinicaltrials.gov/study/NCT02112864